Female fertility depends on several factors including menstrual cycles, ovulation, age, and lifestyle. Experts explain the ...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...

Abstract: Ensuring safety in safety-critical and autonomous systems requires control frameworks that balance performance with strict constraint satisfaction. Model Predictive Control (MPC) naturally ...

The discovery that most ovarian cancers start, not in the ovaries, but the Fallopian tubes, means there may be a way to help prevent a disease that kills about 1000 women in Australia each year. It ...

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Fallopian Tube Cancer Market - A Global and Regional Analysis: Focus on Type, Treatment Type, End User, and Region, 2025-2035" report has been added to ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only ...

The primary function of the middle ear (ME) is to capture environmental sound pressures and transfer them to the cochlea. Efficient ME function requires that the ME be maintained at near-atmospheric ...

Istanbul: CPAP therapy does not affect Eustachian tube function, but understanding its side effects can improve patient compliance, according to a study published in the Journal of Otolaryngology–Head ...

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line ...

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic ...

Niraparib can be used as an option for the maintenance treatment of advanced epithelial (FIGO stages 3 and 4) high-grade ovarian, fallopian tube or primary peritoneal cancer after a response to ...